Hengrui Pharma’s Strategic Leap: Licensing HRS‑1596 to Novartis Boosts Oncology Growth
Hengrui Pharma partners with Novartis to launch HRS‑1596, a precision‑oncology drug targeting B7‑H3, positioning the company at the frontier of high‑margin cancer therapy and offering investors a promising growth play.
4 minutes to read